| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5615131 | Journal of Clinical Lipidology | 2017 | 21 Pages |
Abstract
Our initial experience of PCSK9 inhibition in FH patients in a clinical setting showed comparable reduction in LDL-c levels but more side effects compared with clinical trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Annette M.H. MANP, Mattie J. PhD, Eric J. MD, PhD, Jeanine E. MD, PhD,